Compare HOMB & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOMB | PTCT |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.7B |
| IPO Year | 2006 | 2006 |
| Metric | HOMB | PTCT |
|---|---|---|
| Price | $27.86 | $74.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 17 |
| Target Price | $31.50 | ★ $80.65 |
| AVG Volume (30 Days) | ★ 1.4M | 983.4K |
| Earning Date | 04-15-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.17% | N/A |
| EPS Growth | 19.90 | ★ 264.48 |
| EPS | ★ 0.60 | N/A |
| Revenue | N/A | ★ $264,734,000.00 |
| Revenue This Year | $10.99 | N/A |
| Revenue Next Year | $5.14 | $17.70 |
| P/E Ratio | $45.80 | ★ N/A |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $25.50 | $43.18 |
| 52 Week High | $30.83 | $87.50 |
| Indicator | HOMB | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 63.76 | 60.71 |
| Support Level | $27.80 | $73.41 |
| Resistance Level | $28.59 | $79.67 |
| Average True Range (ATR) | 0.42 | 2.66 |
| MACD | 0.15 | 0.39 |
| Stochastic Oscillator | 95.58 | 97.84 |
Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The company has one reportable segment: The Banking Segment.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.